CBLL Ceribell, Inc.
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1861107 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY31.3%
TTM net income YoY-40.8%
TTM EPS YoY-467.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin89.3%
Operating margin-69.8%
Net margin-68.0%
FCF margin-51.9%
EBITDA margin-68.9%
Returns
ROE-52.5%
ROA-41.5%
ROIC (approx.)-55.5%
Asset turnover0.61x
Leverage & solvency
Liabilities / assets24.8%
Debt / equity0.00x
Current ratio8.18x
Interest coverage-47.39x
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $89.06M | $65.44M |
| Cost of revenue | $10.79M | $8.69M |
| Gross profit | $78.27M | $56.75M |
| R&D expense | $19.14M | $13.56M |
| SG&A expense | $44.45M | $33.84M |
| Operating income | -$58.40M | -$39.71M |
| Interest expense | $1.89M | $1.99M |
| Pretax income | -$53.41M | -$40.45M |
| Income tax | $0 | $0 |
| Net income | -$53.41M | -$40.45M |
| EBITDA | -$57.06M | -$38.57M |
| EPS (basic) | -1.46 | -3.39 |
| EPS (diluted) | -1.46 | -3.39 |
| Weighted avg. shares (diluted) | 36.54M | 11.95M |
| Balance sheet | ||
| Cash & equivalents | $40.48M | $194.37M |
| Short-term investments | $118.78M | — |
| Receivables | $15.05M | $10.88M |
| Inventory | $7.29M | $6.94M |
| Current assets | $186.72M | $217.27M |
| PP&E, net | $2.03M | $2.31M |
| Total assets | $195.80M | $225.41M |
| Current liabilities | $19.19M | $12.99M |
| Total liabilities | $40.47M | $34.25M |
| Shareholders' equity | $155.34M | $191.16M |
| Shares outstanding | 37.49M | 35.85M |
| Cash flow statement | ||
| Operating cash flow | -$40.81M | -$35.04M |
| Capital expenditure | $767,000 | $1.34M |
| Free cash flow | -$41.58M | -$36.38M |
| Investing cash flow | -$118.14M | -$1.60M |
| Financing cash flow | $5.05M | $196.52M |
| Depreciation & amortization | $1.34M | $1.14M |
| Stock-based compensation | $12.22M | $5.41M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.